Sildenafil inhibits human pulmonary artery smooth muscle cell proliferation by decreasing capacitative Ca2+ entry

Journal of Pharmacological Sciences

Volumn 108, Issue 1, 2008, Pages 71-78

  Wang, Cong ^a   Wang, Jun ^b   Zhao, Lan ^c   Wang, Yuexiu ^a,b   Liu, Jie ^b   Shi, Luping ^b   Xu, Meng ^b   Wang, Chen ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Capacitative Ca2+ entry; Pulmonary artery smooth muscle cell; Store operated channel; Transient receptor potential channel

Indexed keywords

1 [2 (4 METHOXYPHENYL) 2 [3 (4 METHOXYPHENYL)PROPOXY]ETHYL] 1H IMIDAZOLE; CALCIUM CHANNEL; CALCIUM ION; EDETIC ACID; ENDOTHELIN 1; GADOLINIUM CHLORIDE; NIFEDIPINE; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; STORE OPERATED CHANNEL; TRANSIENT RECEPTOR POTENTIAL CHANNEL; UNCLASSIFIED DRUG;

ARTICLE; CALCIUM TRANSPORT; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOMETRY; DOSE RESPONSE; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; PULMONARY ARTERY; PULMONARY HYPERTENSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; TRPC1 GENE; WESTERN BLOTTING;

EID: 52949096809     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.08069FP     Document Type: Article

References (28)

1. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43: 13S-24S.
2. Mehran M, Fung YC, Huang W, Remillarda CV, Rubin LJ, Yuan XJ. Cellular and molecular mechanisms of pulmonary vascular remodeling:role in the development of pulmonary hypertension. Microvasc Res. 2004;68:75-103.
3. Remillard CV, Yuan JX. TRP channels, CCE, and the pulmonary vascular smooth muscle. Microcirculation. 2006;13:671-692.
4. Parekh AB, Putney JW Jr. Store-operated calcium channels. Physiol Rev. 2005;85:757-810.
5. Sayin T, Ozenci M. Sustained long-term benefit of sildenafil in primary pulmonary hypertension. Acta Cardiol. 2007;62:47-49.
6. Wharton J, Strange JW, Moller GM, Growcott EJ, Ren X, Franklyn AP, et al. Antiproliferative effects of phospho-diesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med. 2005;172:105-113.
7. Pauvert O, Bonne S, Rousseau E, Marthan R, Savineau JP. Sildenafil alters calcium signaling and vascular tone in pulmonary arteries from chronically hypoxic rats. Am J Physiol Lung Cell Mol Physiol. 2004;287:L577-L583.
8. Tantini B, Manes A, Fiumana E, Pignatti C, Guarnieri C, Zannoli R, et al. Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res Cardiol. 2005;100:131-138.
9. 2+ indicators with greatly improved fluorescence properties. J Biol Chem. 1985;260:3440-3450.
10. 2+ entry in human pulmonary artery endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2003;285:L1233-L1245.
11. Kunichika N, Landsberg JW, Yu Y, Kunichika H, Thistlethwaite PA, Rubin LJ, et al. Bosentan inhibits transient receptor potential channel expression in pulmonary vascular myocytes. Am J Respir Crit Care Med. 2004;170:1101-1107.
12. 2+ entry channel. Proc Natl Acad Sci U S A. 1999;96:2060-2064.
13. 2+ entry and attenuates pulmonary artery smooth muscle cell proliferation. Am J Physiol Lung Cell Mol Physiol. 2002;283: L144-L155.
14. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet. 2003;361:1533-1544.
15. 2+ entry in human pulmonary artery myocytes during proliferation. Am J Physiol Heart Circ Physiol. 2001;280:H746-H755.
16. Wang J, Shimoda LA, Sylvester JT. Capacitative calcium entry and TRPC channel proteins are expressed in rat distal pulmonary arterial smooth muscle. Am J Physiol Lung Cell Mol Physiol. 2004;286:L848-L858.
17. Ohba T, Watanabe H, Murakami M, Takahashi Y, Iino K, Kuromitsu S, et al. Upregulation of TRPC1 in the development of cardiac hypertrophy. J Mol Cell Cardiol. 2007;42:498-507.
18. Bhatia S, Frantz RP, Severson CJ, Durst LA, McGoon MD. Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. Mayo Clin Proc. 2003;78:1207-1213.
19. Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D, et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation. 2003;108:2066-2069.
20. Sastry BK, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol. 2004;43:1149-1153.
21. Black SM, Sanchez LS, Mata-Greenwood E, Bekker JM, Steinhorn RH, Fineman JR. sGC and PDE5 are elevated in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2001;281: L1051-L1057.
22. Rondelet B, Kerbaul F, Van Beneden R, Motte S, Fesler P, Hubloue I, et al. Signaling molecules in overcirculation-induced pulmonary hypertension in piglets: effects of sildenafil therapy. Circulation. 2004;110:2220-2225.
23. Schermuly RT, Kreisselmeier KP, Ghofrani HA, Yilmaz H, Butrous G, Ermert L, et al. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med. 2004;169:39-45.
24. Sebkhi A, Strange JW, Phillips SC, Wharton J, Wilkins MR. Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation. 2003; 107:3230-3235.
25. Yuan JP, Zeng W, Huang GN, Worley PF, Muallem S. STIM1 heteromultimerizes TRPC channels to determine their function as store-operated channels. Nat Cell Biol. 2007;9:636-645.
26. Liao Y, Erxleben C, Yildirim E, Abramowitz J, Armstrong DL, Birnbaumer L. Orai proteins interact with TRPC channels and confer responsiveness to store depletion. Proc Natl Acad Sci U S A. 2007;104:4682-4687.
27. 2+. Handb Exp Pharmacol. 2007;179:527-540.
28. Inoue R, Takahashi S, Kawarabayshi Y, Hai L, Honda A. Role of nitric oxide (NO)/cGMP/protein kinase G (PKG) pathway in negative regulation of vascular transient receptor potential (TRP) channel TRPC6. J Pharmacol Sci. 2007;103 Suppl 1:88P.